Literature DB >> 28389390

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.

Jennifer A Regan1, Yun Cao1, Melanie C Dispenza1, Shuo Ma2, Leo I Gordon2, Adam M Petrich2, Bruce S Bochner3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28389390      PMCID： PMC7366359          DOI： 10.1016/j.jaci.2017.03.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

1.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

2.  Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

Authors:  Donald MacGlashan; Lee A Honigberg; Ashley Smith; Joseph Buggy; John T Schroeder
Journal:  Int Immunopharmacol       Date:  2011-01-14       Impact factor: 4.932

3.  The prevalence, severity, and distribution of childhood food allergy in the United States.

Authors:  Ruchi S Gupta; Elizabeth E Springston; Manoj R Warrier; Bridget Smith; Rajesh Kumar; Jacqueline Pongracic; Jane L Holl
Journal:  Pediatrics       Date:  2011-06-20       Impact factor: 7.124

4.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

5.  Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Authors:  John C Byrd; Bonnie Harrington; Susan O'Brien; Jeffrey A Jones; Anna Schuh; Steve Devereux; Jorge Chaves; William G Wierda; Farrukh T Awan; Jennifer R Brown; Peter Hillmen; Deborah M Stephens; Paolo Ghia; Jacqueline C Barrientos; John M Pagel; Jennifer Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G Diacovo; Amy J Johnson; Richard R Furman
Journal:  N Engl J Med       Date:  2015-12-07       Impact factor: 91.245

6.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

7.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

8.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Authors:  Betty Y Chang; Min Mei Huang; Michelle Francesco; Jun Chen; Jeremy Sokolove; Padmaja Magadala; William H Robinson; Joseph J Buggy
Journal:  Arthritis Res Ther       Date:  2011-07-13       Impact factor: 5.156

9.  Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production.

Authors:  D Hata; Y Kawakami; N Inagaki; C S Lantz; T Kitamura; W N Khan; M Maeda-Yamamoto; T Miura; W Han; S E Hartman; L Yao; H Nagai; A E Goldfeld; F W Alt; S J Galli; O N Witte; T Kawakami
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307
  9 in total
  19 in total

1.  Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy.

Authors:  Melanie C Dispenza; Jacqueline A Pongracic; Anne M Singh; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2018-01-31       Impact factor: 10.793

2.  Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions.

Authors:  Melanie C Dispenza; Jennifer A Regan; Bruce S Bochner
Journal:  Expert Rev Clin Immunol       Date:  2017-08-31       Impact factor: 4.473

Review 3.  The role of basophils as innate immune regulatory cells in allergy and immunotherapy.

Authors:  Salvatore Chirumbolo; Geir Bjørklund; Andrea Sboarina; Antonio Vella
Journal:  Hum Vaccin Immunother       Date:  2018-01-18       Impact factor: 3.452

4.  CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Authors:  Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

5.  Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.

Authors:  Melanie C Dispenza; Rebecca A Krier-Burris; Krishan D Chhiba; Bradley J Undem; Piper A Robida; Bruce S Bochner
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 6.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz
Journal:  Int Arch Allergy Immunol       Date:  2020-03-30       Impact factor: 2.749

7.  Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcεRI-Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge.

Authors:  Shiteng Duan; Britni M Arlian; Corwin M Nycholat; Yadong Wei; Hiroaki Tateno; Scott A Smith; Matthew S Macauley; Zhou Zhu; Bruce S Bochner; James C Paulson
Journal:  J Immunol       Date:  2021-04-28       Impact factor: 5.422

Review 8.  Pathogenesis of IgE-mediated food allergy and implications for future immunotherapeutics.

Authors:  Nicole Ramsey; M Cecilia Berin
Journal:  Pediatr Allergy Immunol       Date:  2021-06-17       Impact factor: 5.464

Review 9.  Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.

Authors:  Melanie C Dispenza; Bruce S Bochner; Donald W MacGlashan
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

10.  Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.

Authors:  Tobias Litzenburger; Jürgen Steffgen; Ewald Benediktus; Fabian Müller; Armin Schultz; Elliott Klein; Meera Ramanujam; Christian Harcken; Alpana Gupta; Jing Wu; Sabrina Wiebe; Xiujiang Li; Mary Flack; Steven J Padula; Sudha Visvanathan; Andreas Hünnemeyer; Jianan Hui
Journal:  Br J Clin Pharmacol       Date:  2020-11-20       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.